The financials
McKesson Corporation by the numbers
McKesson Corporation (MCK) reported revenue of $96.3B in Q4 2026 (quarter ended Mar 31, 2026), up 6.0% from the same quarter a year earlier. That came with a gross margin of 4.2% and net income of $1.68B (1.7% of revenue). For the full year FY2026, revenue was $403.4B (+12% year on year) and net income $4.76B. Its largest segment in Jun 2026 was North American Pharmaceutical at $86.8B, 82% of the disclosed total, well ahead of Oncology And Multispecialty at 13%.
| Income statement | Q4 2026 | Q4 2025 | Change |
|---|---|---|---|
| Revenue | $96.3B | $90.8B | +6.0% |
| Gross profit | $4.04B | $3.64B | +11% |
| Operating income | $2.15B | $1.59B | +35% |
| Net income | $1.68B | $1.26B | +33% |
| Diluted EPS | $13.65 | $9.92 | +38% |
| Operating | Revenue | Share |
|---|---|---|
| North American Pharmaceutical | $86.8B | 82% |
| Oncology And Multispecialty | $14.2B | 13% |
| Medical Surgical Solutions | $2.82B | 2.7% |
| Prescription Technology Solutions | $1.57B | 1.5% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $105.38B (+517%)
Oncology And Multispecialty grew +33% year on yearMedical Surgical Solutions +4.4% year on year
Segment Latestquarter on quarteryear on year
- North American Pharmaceutical$86.77B$86.77BQoQ -year on year +4.9%-+4.9%
- Oncology And Multispecialty$14.22B$14.22BQoQ +12%year on year +33%+12%+33%
- Medical Surgical Solutions$2.82B$2.82BQoQ -1.7%year on year +4.4%-1.7%+4.4%
- Prescription Technology Solutions$1.57B$1.57BQoQ +4.7%year on year +9.2%+4.7%+9.2%
Healthcare
Ranks #216 of 345 by Smart Score